On July 1, 2025 MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, reported two upcoming poster presentations at the 49th Federation of European Biochemical Societies (FEBS) 2025 Congress, hosted by the Turkish Biochemical Society, to be held July 5-9, 2025, in Istanbul, Turkey (Press release, MAIA Biotechnology, JUL 1, 2025, View Source [SID1234654203]). The poster presentations highlight MAIA’s lead telomere-targeting agent and next-generation treatments. The first presentation will be delivered by MAIA Scientific Advisory Board member, Z. Gunnur Dikmen, M.D., Ph.D., Hacettepe University, Faculty of Medicine, Department of Biochemistry in Ankara, Turkey.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Presentation 1
Abstract title: "Telomere-targeting therapeutics RiboTHIO and THIO synergize with radiotherapy and immune checkpoint blockade to suppress lung tumor growth"
Abstract number:
62164
Abstract notation:
LB-R-32-12
Session title:
Cancer Therapy
Session date and time:
July 7, 2025, from 12:30pm to 2:30pm TRT
Presenter:
Z. Günnur Dikmen, M.D., Ph.D.
Abstract access:
Available at FEBS Open Bio Journal after the Congress
Poster Presentation 2
Abstract title: "The effects of telomerase mediated telomere-targeting novel drug candidate compounds on oxidative DNA damage and DNA repair on A549 cells"
Abstract number:
60494
Abstract notation:
P-32-095
Session title:
Cancer Therapy
Session date and time:
July 7, 2025, from 12:30pm to 2:30pm TRT
Presenter:
Gamze Tuna
Abstract access:
Available at FEBS Open Bio Journal after the Congress
"We appreciate the opportunity to participate at the FEBS Congress where the outstanding merits of our first-in-class cancer telomere targeting agents will be featured before a gathering of the top European academic researchers and scientists." said MAIA Chairman and CEO Vlad Vitoc, M.D. "These scientific findings further illustrate the potential of our current and next-generation treatments to synergize with therapies used in several cancer indications."
The most recent data from MAIA’s THIO-101 pivotal Phase 2 clinical trial of ateganosine as a treatment for non-small cell lung cancer (NSCLC) showed median overall survival (OS) of 17.8 months1 in a heavily pre-treated population.